News Ipsen doubles up in TCEs for cancer, adding Biomunex drug Ipsen has expanded its oncology pipeline by licensing a T cell engager (TCE) therapy from Paris-based startup Biomunex for up to $610m.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.